1. Home
  2. OLMA vs UEC Comparison

OLMA vs UEC Comparison

Compare OLMA & UEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLMA
  • UEC
  • Stock Information
  • Founded
  • OLMA 2006
  • UEC 2003
  • Country
  • OLMA United States
  • UEC United States
  • Employees
  • OLMA N/A
  • UEC N/A
  • Industry
  • OLMA Biotechnology: Pharmaceutical Preparations
  • UEC Other Metals and Minerals
  • Sector
  • OLMA Health Care
  • UEC Basic Materials
  • Exchange
  • OLMA Nasdaq
  • UEC Nasdaq
  • Market Cap
  • OLMA 465.4M
  • UEC N/A
  • IPO Year
  • OLMA 2020
  • UEC N/A
  • Fundamental
  • Price
  • OLMA $6.10
  • UEC $7.08
  • Analyst Decision
  • OLMA Strong Buy
  • UEC Strong Buy
  • Analyst Count
  • OLMA 5
  • UEC 2
  • Target Price
  • OLMA $26.25
  • UEC $10.63
  • AVG Volume (30 Days)
  • OLMA 1.1M
  • UEC 7.1M
  • Earning Date
  • OLMA 11-12-2024
  • UEC 12-27-2024
  • Dividend Yield
  • OLMA N/A
  • UEC N/A
  • EPS Growth
  • OLMA N/A
  • UEC N/A
  • EPS
  • OLMA N/A
  • UEC N/A
  • Revenue
  • OLMA N/A
  • UEC $17,203,000.00
  • Revenue This Year
  • OLMA N/A
  • UEC $45,283.93
  • Revenue Next Year
  • OLMA N/A
  • UEC $71.22
  • P/E Ratio
  • OLMA N/A
  • UEC N/A
  • Revenue Growth
  • OLMA N/A
  • UEC N/A
  • 52 Week Low
  • OLMA $5.56
  • UEC $4.06
  • 52 Week High
  • OLMA $16.78
  • UEC $8.93
  • Technical
  • Relative Strength Index (RSI)
  • OLMA 27.05
  • UEC 38.63
  • Support Level
  • OLMA $5.56
  • UEC $7.11
  • Resistance Level
  • OLMA $6.87
  • UEC $7.70
  • Average True Range (ATR)
  • OLMA 0.81
  • UEC 0.43
  • MACD
  • OLMA -0.28
  • UEC -0.15
  • Stochastic Oscillator
  • OLMA 10.12
  • UEC 3.65

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: